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Guilia Pieretti, MD; Jerry A. Shields, MDAbstractPurpose: To review the features and prognosis of uveal melanoma in children.
Methods: Retrospective case series.
Results: Of 122 children with uveal melanoma, there were 53 (43%) male and 69 (57%) female patients. In this group, the mean age
at presentation was 15 years (median 16 years, range 3–20 years). Age at presentation was 0 to 5 years in 4 (3%), 5.1 to 10 years in
14 (11%), 10.1 to 15 years in 43 (35%), and 15.1 to 620 in 61 (50%). Associated ocular melanocytosis was present in 4 (3%). The
melanoma was primarily located in the iris (n = 30, 25%), ciliary body (n = 10, 8%), or choroid (n = 82, 67%). The mean tumor basal
dimension was 9.8 mm and mean thickness was 5.0 mm. The tumor color was pigmented (brown) (n = 102, 84%), nonpigmented
(yellow) (n = 19, 16%), or mixed (n = 25, 21%). Subretinal fluid (n = 66, 54%) and hemorrhage (n = 9, 7%) were noted. Primary treat-
ment involved laser photocoagulation (n = 3, 2%), transpupillary thermotherapy (n = 17, 14%), local tumor resection (n = 26, 21%),
plaque radiotherapy (n = 42, 34%), or enucleation (n = 54, 44%). Kaplan Meier 5, 10, and 20-year estimates for uveal melanoma-
related metastasis were 9%, 9%, and 20%, respectively, for children compared to 15%, 25%, and 36% for all ages.
Conclusion: Uveal melanoma in children tends to occur most often in the teenage years as a pigmented tumor involving the cho-
roid or iris and with mean thickness of 5 mm. Prompt treatment is advised.
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http://dx.doi.org/10.1016/j.sjopt.2013.06.013IntroductionUveal melanoma presents at an average age of 58 years
and is rare in children.1,2 Based on a large series of 8033 pa-
tients with uveal melanoma, only 1% occurred at the age of
20 years or younger.1,3 According to the database of 2493
cases of uveal melanoma from the National Cancer Institute
Surveillance, Epidemiology, and End Results (SEER), uveal
melanoma at all ages was more common in males (4.9 per
million) compared to females (3.7 per million). The mean
age at presentation was 60 years, ranging from 6 years to
100 years.4 The age-specific incidence of uveal melanoma
per million population for 10–14 year old persons was 0.2for males and 0 for females, compared to 20–24 years at
0.4 for males and 0.6 for females, and this peaked at 70–
74 years at 24.5 for males and 17.8 for females.4
In this report, we specifically focus on a large cohort of
uveal melanoma in children and teenagers of age 20 years
or younger. We will review tumor clinical features, treatments
and outcomes. A review of the literature will be provided.Methods
This retrospective, nonrandomized, interventional case
series included all patients classified as children of age
20 years or younger and with a clinical diagnosis of uveale:
al.com
States.
Table 1. Uveal melanoma in 122 children:
Age at presentation by year.
Age (years) Number (%)
0–1 0 (0)
1.1–2 0 (0)
2.1–3 1 (1)
3.1–4 1 (1)
4.1–5 2 (2)
5.1–6 3 (2)
6.1–7 0 (0)
7.1–8 4 (3)
8.1–9 2 (2)
9.1–10 5 (4)
10.1–11 1 (1)
11.1–12 5 (4)
12.1–13 17 (14)
13.1–14 9 (7)
14.1–15 11 (9)
15.1–16 10 (8)
16.1–17 9 (7)
17.1–18 6 (5)
18.1–19 13 (11)
19.1–20 23 (19)
Total 122 (100)
Table 2. Uveal melanoma in 122 children: Clinical features.
Feature Number (%)
Location (n = 122)
Iris 30 (25)
Ciliary body 10 (8)
Choroid 82 (67)
Tumor quadrant (n = 122)
Superior 24 (20)
Nasal 26 (21)
Inferior 42 (34)
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Eye Hospital, Thomas Jefferson University between August
25, 1970, and August 27, 2008. Institutional review board ap-
proval was obtained for this study.
The following data were extracted from the medical re-
cords including patient age at diagnosis (years), gender,
and race. Each child was evaluated for unequivocal ocular
or oculodermal melanocytosis involving eyelid, temporal fos-
sa, palate, sclera, iris, ciliary body, choroid, and orbit (when
possible). Additional data included intraocular pressure
(mmHg), location of tumor epicenter (iris, ciliary body, cho-
roid), largest tumor basal dimension and thickness (mm), tu-
mor configuration (dome, mushroom, tapioca, plateau),
color (pigmented, non-pigmented), subretinal fluid, intraocu-
lar hemorrhage, and extraocular extension. Tumor thickness
was measured by B-scan ocular ultrasonography. All findings
were documented with a large color-coded drawing, anterior
segment and posterior segment photography, fluorescein
angiography when appropriate, anterior and posterior seg-
ment optical coherence tomography when available, ultra-
sound biomicroscopy (for anterior segment tumors) and
ultrasonography (for posterior segment tumors).
The proposed treatment was discussed with the patient
and family and risks and benefits were explained. A signed in-
formed consent was obtained. Systemic monitoring and
screening for metastasis were performed by a medical physi-
cian or oncologist with twice-yearly physical examination and
liver function tests (lactate dehydrogenase, alkaline phospha-
tase, alanine aminotransferase, and aspartate aminotransfer-
ase), once-yearly liver imaging (magnetic resonance imaging,
computed tomography, or ultrasonography), and chest imag-
ing (chest radiograph or computed tomography). The date
and interval to systemic metastasis were recorded.Temporal 23 (19)
Diffuse 4 (3)
Macula 3 (2)
Distance to foveola (mm), mean (median)
[range]
8.6 (4.5), [0 to 25)
Distance to optic disk (mm), mean (median)
[range]
8.5 (4.5), [0 to 25]
Tumor base (mm) mean (median) [range] 9.8 (9.0), [2.5 to
24]
Tumor thickness (mm) mean (median) [range] 5.0 (3.7), [0.5 toStatistical analysis
The clinical features and outcomes (tumor-related metas-
tasis) were then statistically analyzed. Kaplan–Meier analysis
was performed to estimate the cumulative probability of tu-
mor-related metastasis at 3, 5, 10 and 20 years.14]
Tumor configuration (n = 121)
Plateau 12 (10)
Dome 88 (73)
Mushroom 16 (13)
Tapioca 5 (4)
Color (n = 121)
Pigmented 102 (84)
Non-pigmented 19 (16)
Related features (n = 122)
Subretinal fluid 66 (54)
Intraocular hemorrhage 9 (7)
Rupture of Bruch’s membrane 16 (13)
Extraocular extension 1 (1)Results
Of a comprehensive database on 8101 patients with uveal
melanoma managed on the Oncology Service, Wills Eye Hos-
pital during this 38-year period, 122 (1.5%) were young pa-
tients of age 20 years or less. In this group, the mean age
at presentation was 15 years (median 16 years, range 3–
20 years). The youngest patient, age 3 years, demonstrated
a small choroidal melanoma and the next youngest, a 4 year
old had a large, pigmented iris melanoma with angle seeding
and secondary glaucoma. Melanoma by year is listed in
Table 1. Of the 122 pediatric patients with melanoma, age
was 0 to 5 years in 4 (3%), 5.1 to 10 years in 14 (11%), 10.1
to 15 years in 43 (35%), and 15.1 to 620 in 61 (50%). Alterna-
tively, the tumor occurred in children of preteen years (0
to13 years) in 41 (34%) and in those of teenage years (13.1
to 620 years) in 81 (66%).
The patient race was Caucasian (n = 118, 97%), Hispanic
(n = 3, 2%), or Middle Eastern (n = 1, 1%). There were 53
(43%) male patients and 69 (57%) female patients. The tumorinvolved the right eye (n = 54, 44%) or the left eye (n = 68,
56%).
The melanoma features are listed in Table 2. The mela-
noma was primarily located in the iris (n = 30, 25%), ciliary
body (n = 10, 8%), or choroid (n = 82, 67%). (Figs. 1–3) The
mean tumor basal dimension was 9.8 mm and mean thickness
was 5.0 mm. The tumor color was pigmented (brown)
Figure 1. Iris melanoma in a 6 year-old child that showed evidence of
growth from 2007 (A) to 2011 (B), at which time secondary glaucoma and
extensive angle seeding were detected. Following plaque radiotherapy
the tumor regressed (C) and the glaucoma was controlled with topical
therapy. There was no metastasis on 6 year follow up.
Figure 2. Choroidal melanoma in a 19 year-old girl appearing as a lightly
pigmented mass (A) and measuring 11 mm thickness (B). The tumor
responded following plaque radiotherapy. Liver metastases were
detected 2 years later.
Figure 3. Ciliochoroidal melanoma in a 5 year-old boy (A) appearing as a
nonpigmented (B) mass with thickness of 10 mm (C) and managed with
enucleation. There was no metastasis on 7 year follow up.
Uveal melanoma in children and teenagers 199(n = 102, 84%), nonpigmented (yellow) (n = 19, 16%), or
mixed (n = 25, 21%). Associated subretinal fluid was present
in 66 (54%) cases and hemorrhage in 9 (7%).
Presence and location of ocular melanocytosis is listed in
Table 3. Melanocytosis was present in 4 patients (3%) and in-
volved the sclera (n = 2, 2%), iris (n = 1, 1%), and/or choroid
(n = 2, 2%). Primary treatment involved laser photocoagula-
tion (n = 3, 2%), transpupillary thermotherapy (n = 17, 14%),
local tumor resection (n = 26, 21%), plaque radiotherapy
(n = 42, 34%), or enucleation (n = 54, 44%).
Kaplan Meier estimates for melanoma related metastasis
based on age (children versus all ages) are listed in Table 4.
Overall, metastasis at 10 years was 8.8% for children versus
Table 3. Uveal melanoma in 122 children: Related ocular or oculodermal
melanocytosis.
Ocular/Oculodermal melanocytosis Number (%)
Melanocytosis (n = 122 patients)
Ocular/Oculodermal 4 (3)
None 118 (97)
Site of melanocytosis (n = 122 patients)*
Eyelid 0 (0)
Temporal fossa 0 (0)
Palate 0 (0)
Sclera 2 (2)
Iris 1 (1)
Choroid 2 (2)
Orbit 0 (0)
* Some may have more than one site.
200 C.L. Shields et al.25% for all ages and metastasis at 20 years was 20.2% for
children and 36% for all ages. Of the 4 in this series with mel-
anoma and melanocytosis, there were no deaths by mean
3 years follow up (range <1–7 years).Discussion
In 1962, Apt reported on uveal melanoma in children from
the Registry of Ophthalmic Pathology of the Armed Forces
Institute of Pathology (AFIP) and identified 46 cases.5 He
commented that nearly all patients were Caucasian and most
cases occurred during the mid to late teenage years. He
speculated that this acceleration was related to [unproven]
hormonal influence in the development of melanoma. One
important observation was the relative number of tumors in
the iris, representing 19 (41%) of the 46 cases. Unfortunately,
the cohort was not purely melanoma in that 8 (42%) of the 19
iris melanomas and 4 (15%) of the 27 posterior uveal melano-
mas proved to be benign spindle A nevus and not melanoma.
In 1981, Barr et al. revisited the files of the AFIP and found
78 cases of pediatric uveal melanoma.6 They identified 5, 10,
and 15-year mortality for pediatric iris melanoma at 8%, 8%,
and 13% and for pediatric choroid/ciliary body melanoma at
21%, 21%, and 25%. For iris melanoma, risks for death in-
cluded glaucoma, posterior invasion into ciliary body/cho-
roid, diffuse growth pattern, angle involvement, scleral
invasion, necrosis, epithelioid cells, and high mitotic activity.
For choroidal melanoma, factors related to death included
painful red eye, extraocular extension, basal tumor diameter
P10 mm, tumor thickness >2 mm, tumor necrosis, high mito-
tic activity, Bruch’s membrane invasion, and iris/ciliary body
invasion. There were 7 cases of erroneous clinical diagnosis
with unsuspected melanoma before enucleation in that
series.6 In fact, 4 patients had scleral buckle for retinalTable 4. Uveal melanoma-related metastasis using Kaplan–Meier estimates.
Metastasis % at 5 years ± SE % at 10 ye
Children 6 20 years All patients*, all
ages
Children 6
Iris melanoma 9.1 ± 8.7 4.1 + 1.8 –
Ciliary body
melanoma
0 19.0 ± 2.5 0
Choroid melanoma 9.4 ± 5.3 15.2 ± 0.6 9.4 ± 5.3
All sites uveal
melanoma
8.8 ± 4.3 15.0 ± 0.5 8.8 ± 4.3
SE = standard error.
* Compared to published data on 8033 patients with uveal melanoma.1detachment and 2 had filtration surgery for glaucoma before
the diagnosis of melanoma was established, with 3 of these 6
patients succumbing to metastatic disease. They concluded
that uveal melanoma in children should be promptly recog-
nized, avoiding misdirected therapy, and managed as
aggressively as those in adults.
The previous reports emanated retrospectively from a ter-
tiary pathology laboratory with little clinical detail.5,6 In 1965,
Verdaguer et al. reported a clinical series of 17 children with
uveal melanoma and noted no metastatic event over median
5-year follow up.7 In 1991, Shields et al. described a compre-
hensive clinical series of 40 children with uveal melanoma.8
They stated that this represented 1% of the 3706 consecutive
patients managed with uveal melanoma in their tertiary clin-
ical ocular oncology center. There was no previous misdiag-
nosis in this series and misdirected therapy was avoided.
Overall cumulative survival was excellent with only 4% metas-
tasis at 5 years. They stated that this early survival was
encouraging but longer follow up was necessary to under-
stand the true impact of uveal melanoma in children. Part
of the favorable survival was likely related to the detection
of the melanoma when small, avoidance of misdirected ther-
apy, and management at an experienced center for uveal
melanoma. Later, in 2000, an updated clinical database from
this department by Singh et al. added 23 more patients for a
total of 63 pediatric patients with uveal melanoma.9 They ob-
served that oculo(dermal) melanocytosis was 9 times more
common in this cohort than expected in the general popula-
tion. An additional observation was that the early favorable
prognosis appeared to normalize at the 15-year point, more
similar to adults.
In 2012, Shields et al. reviewed 8033 cases of uveal mela-
noma to explore clinical differences in tumor based on age at
presentation.1 Several significant findings (p < 0.05) identi-
fied children (compared to adults older than 60 years) as
more likely to show iris location, smaller tumor size, further
from foveola and optic disk, lack of pigmentation, and less
subretinal fluid and extrascleral extension. Regarding metas-
tasis and death, children and young adults combined showed
more favorable prognosis than older adults (>60 years). In
that analysis, specific metastasis per decade revealed 10-year
rates for children 0–10 years old at 0% and 11–20 years old at
10% compared to adults 61–70 years old at 30%.1
To more clearly understand the prognosis of children ver-
sus adults with uveal melanoma, Kaliki et al. provided a
matched retrospective cohort study on children (620 years)
versus mid-adults (21–60 years) versus older adults
(>60 years).10 The 3 groups were matched for gender, tumor
location, location of anterior margin of tumor, tumor basal
diameter, tumor thickness, and extraocular extension. Kap-ars ± SE % at 20 years ± SE
20 years All patients*, all
ages
Children 6 20 years All patients*, all
ages
6.9 ± 2.7 – 9.5 ± 3.6
33.6 ± 4.1 0 55.3 ± 11.4
25.1 ± 0.9 20.7 ± 11.6 36.2 ± 1.7
25.0 ± 0.8 20.2 ± 11.3 36.0 ± 1.7
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10 years were 1%, 8%, and 8% in children; 8%, 11%, and
26% in mid-adults; and 13%, 16%, and 24% in older adults.
After exclusion of iris melanoma, melanoma metastasis at 3,
5, and 10 years was 2%, 11%, and 18% in children; 9%,
14%, and 21% in mid-adults; and 9%, 34%, and 33% in older
adults. After adjusting for tumor diameter, the metastatic
rate was found to be lower in children compared to mid-
adults (0 = 0.042, HR 3.00) and older adults (p = 0.007, HR
4.20).
In our present cohort of 122 children with uveal melanoma
evaluated herein, we found specific age at presentation was 0
to 5 years in 4 (3%), 5.1 to 10 years in 14 (11%), 10.1 to
15 years in 43 (35%), and 15.1 to 620 in 61 (50%). Ocular mel-
anocytosis was present in 4 (3%). The mean tumor basal
dimension was 9.8 mm, 5.0 mm in thickness, and pigmented
in 102 cases (84%). The tumor was located in the iris (n = 30,
25%), ciliary body (n = 10, 8%), or choroid (n = 82, 67%). The
patients in this report have been included in previous smaller
studies8,9 or a matched cohort study,10 with the purpose of
this investigation to detail precise clinical features.
Ocular melanocytosis is a known precursor to uveal mela-
noma.11–13 This condition was noted in 3% of 7872 patients
with uveal melanoma.13 In this analysis of children with uveal
melanoma, melanocytosis was present in 3%. Based on pub-
lished data, patients with uveal melanoma and ocular melan-
ocytosis have double the risk for metastasis compared to
those without melanocytosis.13 Of the 4 in this pediatric ser-
ies with melanoma and melanocytosis, there were no deaths
on relatively short mean 3-year follow up (range <1–7 years).
Genetic markers have become important in the prognosti-
cation of uveal melanoma.14–19 Evidence confirms that chro-
mosomal mutations in 3, 6, and 8 or gene expression
abnormalities can lead to an increased risk for melanoma
metastasis.14,15,18,19 Further information on mutations in
BAP1, GNAQ, and GNA11 could be major events leading to
melanoma development or metastatic events.16,17 Levasseur
et al. identified GNAQ mutation in an 18 month-old child with
congenital uveal melanoma.20 Van Raamsdonk et al. found
that 83% of uveal melanomas show somatic mutation in either
GNAQ or GNA11, involved in the mitogen-activated protein
kinase pathway.16 This could represent one of the earliest
mutations in the ultimate development of melanoma.
In conclusion, uveal melanoma in children tends to be
smaller and more often in the iris compared to older adults.
Similar to adults, ocular melanocytosis can be a precursor
condition. Our understanding of the prognosis of melanoma
in this subset of patients has evolved over 50 years. It remains
important for all patients, whether children or adults, to
achieve early detection of melanoma when the tumor is small
to minimize the risk for metastasis. Children with melanoma
show slightly better systemic prognosis when matched to
older adults. The reason for better prognosis in young age
is unknown but could be partly due to smaller tumor, more
robust immune system, and speculated fewer genetic
alterations.
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